HCPCS
J3385
1 unit = 100 units
Phase 1
Identify what you're billing
Confirm the right ERT brand, the 100-unit J3385 billing-unit basis, and the patient's dosing schedule.
Gaucher disease treatment landscape Verified May 2026
VPRIV is one of three IV ERTs for Type 1 Gaucher disease. It came to market in February 2010 amid the Cerezyme supply crisis and is now a class staple used both as first-line therapy and as the standard switch target during imiglucerase shortages.
Type 1 Gaucher disease (the most common form, >90% of cases) is treated either by replacing the deficient glucocerebrosidase enzyme (ERT, IV, medical benefit) or by reducing substrate accumulation (SRT, oral, pharmacy benefit). All three IV ERTs target the same enzyme deficiency; choice is driven by payer formulary, infusion-center logistics, immunogenicity history (lower rate of antibody formation has been reported for velaglucerase alfa vs imiglucerase), and supply stability.
| Drug | HCPCS | Class | Manufacturer | Route | Schedule |
|---|---|---|---|---|---|
| VPRIV (velaglucerase alfa) | J3385 | IV ERT (gene-activated human cell line) | Takeda (originator Shire) | IV (60 min) | 60 units/kg q2w |
| Cerezyme (imiglucerase) | J1786 | IV ERT (CHO cell line) | Sanofi Genzyme | IV (1–2 hr) | 60 IU/kg q2w (or 2.5 IU/kg 3×/wk) |
| Elelyso (taliglucerase alfa) | J3060 | IV ERT (plant-cell expressed) | Pfizer | IV | 60 units/kg q2w |
| Cerdelga (eliglustat) | Pharmacy benefit | Oral SRT | Sanofi Genzyme | PO BID/QD | CYP2D6 metabolizer-status dependent |
| Zavesca (miglustat) | Pharmacy benefit | Oral SRT | Janssen | PO TID | Adults intolerant of ERT only |
VPRIV is the reference brand for J3385. No biosimilars exist for velaglucerase alfa. VPRIV
and Elelyso are not biosimilars to Cerezyme — they are independently developed recombinant
enzymes that compete clinically and contractually but each carry their own permanent HCPCS, NDC, and ASP.
Lifelong therapy commitment. Discontinuation of any Gaucher ERT generally leads to cytopenia
and organomegaly recurrence within 12–18 months. Reauthorization is annual but withdrawal of coverage
in stable, treatment-adherent patients is rare.
For other lysosomal storage disorder ERTs in the CareCost library, see Fabrazyme (agalsidase beta, Fabry disease), Elfabrio (pegunigalsidase alfa, Fabry), Aldurazyme (laronidase, MPS I), Vimizim (elosulfase alfa, MPS IVA), Naglazyme (galsulfase, MPS VI), Elaprase (idursulfase, Hunter syndrome), and Xenpozyme (olipudase alfa, acid sphingomyelinase deficiency).
Brand interchangeability & payer formulary management Verified May 2026
VPRIV is a common switch target from Cerezyme during supply disruptions or antibody-mediated efficacy loss. Switching requires a new PA and a new HCPCS on the claim.
While VPRIV, Cerezyme, and Elelyso are not legally interchangeable at the pharmacy or claim level (each has its own NDC and HCPCS), payers manage them as a single therapeutic class for formulary purposes. Switching between brands is clinically straightforward and historically well-tolerated (most centers transition at the next scheduled q2w dose without washout), but each switch requires a separate prior authorization and a new claim line under the new HCPCS.
| Switching scenario | Payer-side action | Coding-side action |
|---|---|---|
| Cerezyme → VPRIV (supply / shortage / formulary preference) | New PA for J3385; cite supply-disruption-or-preference rationale; reference the prior Cerezyme regimen | Stop billing J1786; bill J3385 with VPRIV NDC 54092-0700-04; same E75.22 dx; admin code stays 96365 (60-min infusion) |
| Cerezyme → VPRIV (antibody-mediated efficacy loss) | New PA for J3385; submit anti-imiglucerase IgG documentation + biomarker trend (chitotriosidase / lyso-Gb1) showing loss of response | Same as above |
| VPRIV → Cerezyme (formulary mandate) | New PA for J1786; cite plan formulary change | Stop J3385; bill J1786 with Cerezyme NDC; admin time extends to 96365 + 96366 (1–2 hr Cerezyme infusion) |
| VPRIV → Elelyso | New PA for J3060 at clinically equivalent unit/kg | Stop J3385; bill J3060 with Elelyso NDC |
| VPRIV → Cerdelga (oral SRT) | New PA under pharmacy benefit; CYP2D6 genotype confirmation | Stop infusion claims; transition to retail/specialty pharmacy fill |
Do not bill J3385 for Cerezyme or Elelyso administrations. Each ERT has its own permanent
HCPCS — mismatched code/product pairs trigger immediate denial and recoupment, and may flag a
compliance review. Verify NDC on the vial matches the HCPCS on the claim every time.
Dosing & unit math FDA label verified 2025
From FDA prescribing information (BLA 125249, approved Feb 26, 2010).
Adult & pediatric Type 1 Gaucher (FDA-labeled)
- 60 units/kg IV every 2 weeks as a 60-minute infusion — FDA-labeled maintenance dose; 26 doses/year
- FDA-labeled for pediatric patients ≥4 years and adults
- Dose individualized based on hemoglobin, platelet count, hepatic and splenic volume, bone disease, and biomarker response (chitotriosidase, glucosylsphingosine / lyso-Gb1)
- Some patients are stable on maintenance doses as low as 15–30 units/kg q2w once therapeutic goals achieved — specialist-directed
- Initial dose: same 60 units/kg q2w; no separate loading regimen
Switch dosing from Cerezyme
- Patients switching from Cerezyme typically maintain the same units/kg/dose at the same q2w interval (unit-for-unit clinical equivalence; both products dosed in glucocerebrosidase activity units)
- First VPRIV dose is given at the next scheduled q2w infusion date — no washout
- Monitor for infusion-associated reactions; titrate infusion rate if needed
Unit math — the 100-unit J3385 billing unit
1 J3385 billing unit = 100 units of velaglucerase alfa. Always divide the total drug units administered by 100 before entering the unit count on the claim. Pediatric and low-weight adult doses produce small J3385 counts (often 9–25 units per dose); high-weight adults produce counts in the 35–60 range. Both are normal — what's never normal is a 3- or 4-digit J3385 unit count, which indicates the biller entered drug units directly.
Worked example — standard adult dose (70 kg patient, 60 units/kg q2w)
# Calculate dose in drug units
70 kg × 60 units/kg = 4,200 units per dose
# Convert drug units to J3385 billing units (÷ 100)
4,200 units ÷ 100 units/billing unit = 42 J3385 billing units administered
# Vial calculation (400-unit lyophilized SDV)
4,200 units ÷ 400 units/vial = 10.5 vials → round up to 11 vials
Total drug drawn: 11 × 400 = 4,400 units
Discarded: 4,400 − 4,200 = 200 units = 2 J3385 billing units waste
# Claim lines
Line 1: J3385 / JZ / 42 units (administered)
Line 2: J3385 / JW / 2 units (discarded)
Admin: 96365 × 1 unit (60-min therapeutic IV, non-chemo)
ICD-10: E75.22 (+ organ codes per encounter)
# Year-1 totals (q2w schedule, 26 doses)
Total drug billing units (admin): 1,092 (26 × 42)
Total waste billing units: 52 (26 × 2)
Total drug cost (Q2 2026 ASP+6%): ~$444,051 before sequestration (administered + waste)
70 kg × 60 units/kg = 4,200 units per dose
# Convert drug units to J3385 billing units (÷ 100)
4,200 units ÷ 100 units/billing unit = 42 J3385 billing units administered
# Vial calculation (400-unit lyophilized SDV)
4,200 units ÷ 400 units/vial = 10.5 vials → round up to 11 vials
Total drug drawn: 11 × 400 = 4,400 units
Discarded: 4,400 − 4,200 = 200 units = 2 J3385 billing units waste
# Claim lines
Line 1: J3385 / JZ / 42 units (administered)
Line 2: J3385 / JW / 2 units (discarded)
Admin: 96365 × 1 unit (60-min therapeutic IV, non-chemo)
ICD-10: E75.22 (+ organ codes per encounter)
# Year-1 totals (q2w schedule, 26 doses)
Total drug billing units (admin): 1,092 (26 × 42)
Total waste billing units: 52 (26 × 2)
Total drug cost (Q2 2026 ASP+6%): ~$444,051 before sequestration (administered + waste)
Worked example — pediatric (25 kg child, 60 units/kg q2w)
# Dose
25 kg × 60 units/kg = 1,500 units per dose → 15 J3385 billing units
Vials: 1,500 ÷ 400 = 3.75 → 4 vials drawn (1,600 units)
Waste: 100 units = 1 J3385 billing unit (JW)
Line 1: J3385 / JZ / 15 units
Line 2: J3385 / JW / 1 unit
Admin: 96365 × 1 unit (60-min infusion)
25 kg × 60 units/kg = 1,500 units per dose → 15 J3385 billing units
Vials: 1,500 ÷ 400 = 3.75 → 4 vials drawn (1,600 units)
Waste: 100 units = 1 J3385 billing unit (JW)
Line 1: J3385 / JZ / 15 units
Line 2: J3385 / JW / 1 unit
Admin: 96365 × 1 unit (60-min infusion)
Rounding rule for the JW waste line: J3385 is billed in whole 100-unit increments. Partial
billing units (e.g., 0.5) are not accepted. Round the waste up to the next whole J3385 unit only when the
discarded drug actually exceeds the prior whole-unit threshold. CMS guidance is to bill the exact discarded
amount in the smallest increment supported by the descriptor — for J3385 that is 100 units.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Strength | Package Size | Units/Vial |
|---|---|---|---|
54092-0700-04 (11) / 54092-700-04 (10) |
400 units velaglucerase alfa | Lyophilized powder, single-dose vial — 1 vial per carton | 400 drug units = 4 J3385 billing units per vial |
Use carton-level (11-digit) NDC on the claim form. Vial-level NDC entry triggers payer
denial. VPRIV is shipped in single-dose 400-unit vials only — all dose levels are achieved by
compounding multiple vials. This is why waste is unavoidable on weight-based dosing.
Reconstitution: Each 400-unit vial is reconstituted with 4.3 mL of sterile water for
injection (yielding ~100 units/mL withdrawable). Withdrawn doses are diluted to a final volume of 100 mL
in 0.9% sodium chloride for IV infusion over 60 minutes. Use a 0.2 micron in-line filter. Do not shake
the reconstituted vial — gentle swirl only.
Phase 2
Code the claim
Therapeutic IV admin code, JZ + JW for waste, and the E75.22 anchor diagnosis.
Administration codes CPT verified May 2026
VPRIV is non-chemo enzyme replacement therapy — therapeutic IV codes only. The FDA-labeled 60-minute infusion fits cleanly into CPT 96365 (initial, up to 1 hour).
| Code | Description | When to use |
|---|---|---|
96365 |
Therapeutic IV infusion (non-chemo); initial, up to 1 hour | Primary code for VPRIV. Always required for the first hour of infusion; the FDA-labeled 60-minute infusion fits in a single unit of 96365. |
96366 |
Therapeutic IV infusion; each additional hour | Add only if needed. Standard VPRIV infusion is 60 minutes (single 96365 unit). Add 96366 only if the infusion is slowed (prior reaction, pediatric titration, central-line considerations) and crosses into a second hour. |
96413 / 96415 |
Chemotherapy IV administration codes | NOT appropriate. VPRIV is enzyme replacement therapy, not chemotherapy or complex biologic. CPT chemo admin codes do not apply. |
Why therapeutic IV (not chemo IV): CPT chemo admin codes (96409–96425) apply to
complex monoclonal antibodies, cytotoxic agents, and high-complexity biologics. Velaglucerase alfa is a
recombinant enzyme — biochemically a protein replacement therapy — and is billed under
therapeutic infusion codes per AMA classification.
Common over-billing error: Adding 96366 reflexively to every VPRIV claim. The FDA-labeled
infusion is 60 minutes — bill 96365 only unless the chart documents a longer actual infusion time
and the clinical reason for slowing. Stacking unnecessary additional-hour units triggers chart-pull audits.
Modifiers CMS verified May 2026
JZ + JW — both apply on virtually every claim
VPRIV is uniquely vulnerable to fixed-vial waste: only one vial size (400 units) exists, but dosing is weight-based at 60 units/kg. A 70 kg patient at 60 units/kg needs 4,200 units but must draw 11 vials (4,400 units), leaving 200 units of waste = 2 J3385 billing units. Bill JW with the discarded units on a separate claim line, AND JZ on the administered units per CMS's July 2023 single-dose container policy. Every J3385 claim must carry one of JZ or JW.
| Modifier | When | Worked example (70 kg pt, 60 units/kg) |
|---|---|---|
JZ | Administered units, no waste on this line (required since 7/1/2023 on every SDV claim with zero waste on that line) | Line 1: J3385 / JZ / 42 units (4,200 drug units administered) |
JW | Discarded units from single-dose vial (required since 7/1/2023 when any waste exists) | Line 2: J3385 / JW / 2 units (200 drug units discarded) |
Common error: Failing to bill the JW waste line. CMS audits routinely catch this on
weight-based ERTs. Wasted drug from single-dose vials is reimbursable but must be reported on a separate
line with JW — this is not optional accounting, it's a CMS billing requirement.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the VPRIV infusion (e.g., annual disease monitoring visit combined with the scheduled infusion). Routine pre-infusion clinical assessment is bundled into the infusion service and does not warrant a separate E/M.
340B modifiers (JG, TB)
For 340B-acquired VPRIV, follow your MAC's current 340B modifier policy. Takeda's billing materials do not provide 340B-specific instructions; defer to MAC LCD and your hospital's 340B compliance team.
ICD-10-CM diagnosis coding FY2026 verified May 2026
E75.22 is the primary anchor for all Gaucher disease claims; supplementary codes document organ-system findings that support medical necessity.
| ICD-10 | Description | Use as |
|---|---|---|
E75.22 | Gaucher disease | Primary diagnosis — required on every claim |
D69.6 | Thrombocytopenia, unspecified | Secondary — supports hematologic indication |
D64.9 | Anemia, unspecified | Secondary — supports hematologic indication |
K76.89 | Other specified diseases of liver | Secondary — documents hepatosplenomegaly findings |
R16.0 / R16.1 / R16.2 | Hepatomegaly / splenomegaly / hepatosplenomegaly | Alternate organomegaly documentation |
M89.9 | Disorder of bone, unspecified | Secondary — supports skeletal-disease indication |
M85.80 | Other specified disorders of bone density and structure | Alternate skeletal documentation (Erlenmeyer flask deformity, marrow infiltration, infarction) |
M87.x | Osteonecrosis (avascular necrosis) | Specific skeletal complication; code to anatomic site (e.g., M87.051 right femur) |
R53.83 | Other fatigue | Optional — supports symptomatic burden |
E75.22 alone is rarely sufficient for PA. Most payers require ICD-10 plus enzyme assay
(acid β-glucosidase activity in leukocytes or fibroblasts) plus GBA gene mutation analysis (two
pathogenic variants) plus at least one organ-system finding (cytopenia, organomegaly, skeletal disease,
or elevated biomarker). Document all relevant secondary diagnoses in the encounter note to support the
claim and reauthorization.
Site of care & place of service Verified May 2026
Major commercial payers run aggressive site-of-care utilization management on lysosomal storage disorder ERTs. Stable VPRIV patients are routinely steered out of hospital outpatient (HOPD) into office, freestanding ambulatory infusion suite, or home infusion settings after the first 3 months of incident- free infusions.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician office (genetics / heme / metabolic) | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Freestanding ambulatory infusion center (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored after the first 3 months of stable in-clinic infusions |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after stabilization |
| Patient home | 12 | CMS-1500 (with home infusion vendor) | Common for stable Gaucher patients after the first 3 months; ERT-experienced home nursing required |
Home infusion is well-established for VPRIV. After approximately 3 months of incident-free
in-clinic infusions, most stable adult patients are eligible for home infusion via a contracted specialty
pharmacy plus home nursing vendor. The 60-minute infusion duration is short enough that home nursing visits
are operationally efficient. Emergency response plan, reaction medications, and rate-titration protocols
must be on hand at first-dose home infusions.
Site-of-care denials are the #1 cause of unexpected commercial coverage loss for established VPRIV
patients. Build the SOC transition into the patient's care plan from the start — document
the 3-month observation period, the absence of reactions, and the patient's clinical stability before
submitting the SOC change PA.
Claim form field mapping Takeda OnePath 2025
From Takeda OnePath reimbursement materials and CMS-1500 / 837P field standards.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider (geneticist, hematologist, or metabolic specialist) |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + 54092-0700-04 + UN + total vials drawn (e.g., UN11 for 70 kg dose) |
| HCPCS J3385 + JZ (administered units) | 24D (drug line 1) | Bill in J3385 units (drug units ÷ 100) — e.g., 42 for 4,200 drug units |
| HCPCS J3385 + JW (discarded units) | 24D (drug line 2) | Separate line; report wasted drug units ÷ 100 — e.g., 2 for 200 drug units waste |
| CPT 96365 (admin line, initial hour) | 24D | 1 unit; therapeutic IV initial (60-min infusion) |
| CPT 96366 (additional hours) | 24D | Only if infusion actually extends past 60 minutes |
| ICD-10 primary | 21 | E75.22 — required |
| ICD-10 secondary (organ findings) | 21 | D69.6, D64.9, K76.89, M89.9, M87.x as applicable |
| PA number | 23 | Required by all major payers; lifelong therapy → reauth annually |
Worked CMS-1500 example (70 kg adult, 60 units/kg dose):
Line 1 = J3385 / JZ / 42 units / NDC
54092-0700-04 / UN11 / E75.22.
Line 2 = J3385 / JW / 2 units / same NDC / E75.22.
Line 3 = 96365 / 1 unit / E75.22.
Total billed drug units on this encounter: 44 J3385 (42 admin + 2 waste).
Phase 3
Get paid
Diagnostic confirmation (enzyme assay + GBA mutation) is the PA gatekeeper. Takeda OnePath handles BI / PA support end-to-end.
Payer policy snapshot Reviewed May 2026
All major payers gate VPRIV behind diagnostic confirmation and specialist consultation. Brand selection within the ERT class is increasingly formulary-driven.
| Payer | PA? | Diagnostic requirements | Brand preference |
|---|---|---|---|
| UnitedHealthcare Lysosomal Storage Disorder ERT medical drug policy |
Yes | E75.22 + acid β-glucosidase enzyme assay + GBA gene mutation analysis + geneticist or hematologist consult + at least one organ-system finding | Cerezyme, VPRIV, Elelyso all on policy; preferred brand rotates by contract year and supply landscape; VPRIV often preferred during Cerezyme supply constraints |
| Aetna CPB on Gaucher disease therapies |
Yes | Same as above + clinically significant disease finding (cytopenia, organomegaly, or skeletal disease) | Aligned with NCCN/ASH/MGCC guidance; class parity |
| BCBS plans Vary by plan |
Yes | Generally aligned with ICGG Gaucher Registry / MGCC consensus criteria | Plan-specific; some plans mandate VPRIV-first as preferred ERT |
| Medicare (MAC LCDs) No NCD; per-MAC framework |
Documentation | Covered with E75.22 + diagnostic confirmation; local MAC LCDs may exist for LSD ERTs | Class-neutral; ASP-based payment by HCPCS |
Step therapy
Step therapy within the ERT class (e.g., requiring Cerezyme or Elelyso failure before VPRIV) is uncommon but plan-specific. Step therapy from oral SRT (Cerdelga) into IV ERT is generally not required — ERT remains the standard of care for newly diagnosed Type 1 Gaucher in patients with significant disease burden.
Reauthorization
Annual reauthorization is the norm. Submit current Hgb, platelet count, hepatic and splenic volumes (typically by MRI or volumetric ultrasound), bone disease assessment (MRI bone marrow burden score, DXA, or symptom diary), and biomarker trend (chitotriosidase or glucosylsphingosine / lyso-Gb1). Documented stability or improvement on therapy supports continued coverage; loss of response prompts brand switch or biomarker workup for antibody-mediated inhibition.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from the CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J3385
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions · Next update: July 1, 2026 (Q3 2026)
ASP + 6%
$388.157
per billing unit (100 units of velaglucerase alfa)
60 units/kg dose, 70 kg pt
$16,302.59
42 J3385 billing units (4,200 drug units)
Annual q2w (26 doses)
$423,867
administered drug only, before waste
Annualized cost (administered + waste, 70 kg adult): 26 doses × (42 + 2) billing
units × $388.157 = ~$444,051/year (Medicare ASP+6%). After ~2% sequestration:
~$433,000/year actual paid. Waste is reimbursed because vials are single-dose — do not omit the
JW line.
ASP refreshes automatically. The figures above are pulled live from CareCost's underlying
ASP layer (Q2 2026: $388.157/billing unit). Q3 2026 figures will appear here automatically when CMS
publishes the next quarterly file on July 1, 2026. Recent trend (rounded to 2 decimals for readability;
the live binding above always reflects the current CMS quarter): $374.36 (Q2 2025) → $380.18
(Q3 2025) → $381.36 (Q4 2025) → $386.43 (Q1 2026) → $388.157 (Q2 2026) — slow
upward drift consistent with stable ERT pricing.
Coverage
VPRIV is covered by all MACs under their generic Part B drug-coverage framework with appropriate E75.22 + diagnostic documentation. No NCD specific to velaglucerase alfa. Local MAC LCDs may exist for lysosomal storage disorder ERTs; verify per jurisdiction.
Code history
- J3385 — permanent code, descriptor "Injection, velaglucerase alfa, 100 units"; in use since shortly after FDA approval (Feb 26, 2010)
Patient assistance — Takeda OnePath Takeda verified May 2026
- Takeda OnePath: 1-866-888-0660 — the consolidated Takeda rare-disease patient services program covering VPRIV. Provides benefits investigation, prior authorization assistance, appeal support, copay program enrollment, free-drug program screening, nurse case management, and infusion-site coordination.
- Commercial copay assistance: available for eligible commercially-insured patients (federally restricted — excludes Medicare, Medicaid, TRICARE, VA, and other federal-program patients per anti-kickback statute)
- Patient assistance program (PAP): free product for uninsured / underinsured patients meeting income criteria (FPL threshold; verify current cutoff with Takeda OnePath at enrollment)
- Foundations (Medicare / federal-program patients): National Gaucher Foundation, PAN Foundation, HealthWell Foundation, Patient Advocate Foundation — verify open lysosomal storage disease / Gaucher disease funds quarterly (foundation funds open and close based on donor cycles)
- Specialty pharmacy distribution: Takeda OnePath coordinates VPRIV delivery through a limited network of specialty pharmacies; site of care (provider office vs home infusion) determines the specific distribution path
- Web: takedaonepath.com · enrollment form available for HCP-initiated patient enrollment
Need to model what a specific Gaucher patient will actually pay after copay assistance, deductible,
coinsurance, and OOP max for lifelong q2w therapy?
Run a CareCost Estimate — J3385 pre-loaded.
Phase 4
Fix problems
100-unit basis error, missing JW waste line, and switch-from-Cerezyme rationale are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units appear inflated 100× | Billed drug units as J3385 units instead of dividing by 100 | Recall and resubmit with J3385 units = drug units ÷ 100. A 4,200-unit dose is 42 J3385 units, not 4,200. |
| PA denied — Gaucher diagnosis not confirmed | PA submitted without enzyme assay or GBA mutation results | Submit acid β-glucosidase enzyme assay results (leukocytes or fibroblasts) AND GBA gene mutation analysis (two pathogenic variants) and resubmit PA. Both are typically required. |
| PA denied — missing baseline disease markers | PA submitted without documented organ-system finding | Submit current Hgb, platelet count, hepatic/splenic volume (volumetric imaging), bone disease assessment, and biomarker level (chitotriosidase or lyso-Gb1). At least one significant finding is typically required. |
| Switch from Cerezyme without medical necessity | VPRIV PA submitted without rationale for the brand switch | Document the switch reason: supply disruption, antibody-mediated efficacy loss (anti-imiglucerase IgG + biomarker decline), persistent infusion reactions, or payer formulary mandate. Without rationale, payers will reject and route patient back to prior brand. |
| Wrong admin code (96413) | Chemo IV billed instead of therapeutic IV | Resubmit with 96365 (single unit covers the 60-min infusion). Velaglucerase alfa is enzyme replacement, not chemotherapy. |
| JW waste line missing | Wasted drug from 400-unit vials not reported | Add J3385 / JW line with discarded J3385 units (drug units waste ÷ 100). Single-dose vial waste is reimbursable but must be billed. |
| JZ missing on no-waste claim | Single-dose vial claim without JZ on administered units | Add JZ. Required since 7/1/2023 on every single-dose container claim with no waste on that line. |
| Wrong brand HCPCS | J1786 (Cerezyme) or J3060 (Elelyso) billed for VPRIV administration | Resubmit with J3385 and VPRIV NDC 54092-0700-04. Each ERT brand has its own permanent code. |
| Site-of-care denial (HOPD) | HOPD administration after stabilization on commercial plan with site-of-care UM | Move to office (POS 11), AIC (POS 49), or home (POS 12). Submit medical necessity letter if HOPD required for clinical reasons (history of severe reaction, complex vascular access). |
| Annual reauth not approved | Reauth submitted without current biomarker, organ size, or hematologic data | Submit current Hgb, platelets, hepatic/splenic volume, bone assessment, and biomarker trend showing stability or improvement. |
Frequently asked questions
What is the HCPCS code for VPRIV?
VPRIV (velaglucerase alfa) is billed under HCPCS J3385 — "Injection, velaglucerase
alfa, 100 units." One billing unit equals 100 units of drug, NOT 1 unit and NOT 1 mg.
The most common biller error is treating one J3385 unit as one drug unit: a 4,200-unit dose is billed
as 42 J3385 units, not 4,200. Submitting 4,200 overstates the claim by 100× and triggers immediate
payer recoupment.
VPRIV vs Cerezyme vs Elelyso — how do payers and clinicians choose?
All three are recombinant glucocerebrosidase ERTs for Type 1 Gaucher disease, given IV every 2 weeks at clinically equivalent doses (60 units/kg q2w). VPRIV (J3385, Takeda, FDA Feb 2010) is gene-activated human cell-line expressed. Cerezyme (J1786, Sanofi Genzyme, FDA 1994) is CHO-expressed and the original ERT. Elelyso (J3060, Pfizer, FDA 2012) is plant-cell expressed. Each carries its own HCPCS, NDC, and ASP — they are not pharmacy-interchangeable. Payer choice is typically formulary- and contract-driven. VPRIV is the common switch target during Cerezyme supply disruptions, dating from the 2009–2010 Cerezyme contamination shutdown that drove VPRIV's accelerated approval.
Is genetic testing or enzyme testing required for Gaucher diagnosis?
Both are typically required for payer PA. The gold-standard diagnostic workup combines (1) acid β-glucosidase enzyme assay — demonstrating low enzyme activity in leukocytes or fibroblasts — AND (2) GBA gene mutation analysis identifying two pathogenic variants. Enzyme assay alone can produce false-positives from pseudo-deficiency alleles; mutation analysis confirms the diagnosis and is also used to differentiate Type 1 (no neurologic involvement) from Type 2/3 (neuronopathic forms). Most major payers require results from both before approving any Gaucher ERT.
Is home infusion eligible for VPRIV?
Yes. Per the FDA label and Takeda OnePath materials, home infusion is appropriate for stable patients after the first 3 months of in-clinic infusions without infusion-associated reactions. Most commercial payers and Medicare home infusion programs cover VPRIV at home with an ERT-experienced specialty pharmacy + nursing vendor. POS 12 on the claim form. Emergency response plan and reaction medications must be on hand, especially at the first home dose.
What is the pediatric dose for VPRIV?
Same weight-based regimen as adults: 60 units/kg IV every 2 weeks as a 60-minute infusion. FDA-labeled for pediatric patients aged 4 years and older. Pediatric monitoring panel adds growth velocity, pubertal development tracking, and pediatric bone marrow burden assessment to the standard adult workup. Dosing units (per kg) are the same; small-weight patients simply produce small J3385 unit counts — e.g., a 25 kg child is 15 J3385 units per dose.
Does VPRIV cover Gaucher-related bone disease?
Yes. VPRIV (like all Type 1 Gaucher ERTs) addresses systemic Gaucher manifestations including bone disease. Skeletal complications (bone pain, infarction, AVN, Erlenmeyer flask deformity, osteopenia, pathologic fracture) are coded as M89.9, M85.80, or specific anatomic codes (e.g., M87.x for osteonecrosis). Improvement in bone marrow burden score on MRI and reduction in bone pain are recognized ERT response goals. ERT does not penetrate the central nervous system, so Type 3 (neuronopathic) Gaucher patients still develop progressive neurologic disease despite systemic improvement.
What administration CPT do I use for VPRIV?
96365 (initial therapeutic IV infusion, up to 1 hour) is the primary — and usually
only — admin code. The FDA-labeled VPRIV infusion is 60 minutes, which fits in a single 96365
unit. Add 96366 (each additional hour) only if the infusion actually extends past 60
minutes (slowed rate for prior reaction, central-line considerations, etc.) and the chart documents
the extended time. Do NOT bill 96413/96415 — VPRIV is enzyme replacement therapy, not
chemotherapy.
What is the Medicare reimbursement for J3385?
For Q2 2026, the Medicare Part B payment limit for J3385 is $388.157 per billing unit (100 units of velaglucerase alfa) under ASP + 6%. A 60 units/kg dose for a 70 kg patient (4,200 units = 42 billing units) reimburses at approximately $16,302.59 per infusion, or roughly $423,867/year on a q2w schedule (26 doses, administered drug only, before waste). Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. ASP is updated quarterly by CMS.
Does VPRIV have a Boxed Warning?
Yes. The current VPRIV FDA label (revised November 26, 2024) carries a BOXED WARNING for HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS. Anaphylaxis can occur both during early treatment and after extended therapy. VPRIV must be administered under the supervision of a healthcare provider with appropriate medical support readily available; if a severe reaction occurs, immediately discontinue VPRIV and initiate appropriate treatment (including epinephrine). Additional W&P: lower rate of anti-drug antibody formation than imiglucerase, which is part of the clinical rationale for switching antibody-positive Cerezyme patients to VPRIV.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — VPRIV (velaglucerase alfa) Prescribing Information
- Takeda OnePath — VPRIV patient services and HCP reimbursement materials
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J3385 reference
- UnitedHealthcare — Lysosomal Storage Disorder ERT medical drug policy
- Aetna CPB — Enzyme Replacement Therapy for Gaucher Disease
- National Gaucher Foundation — clinician resources
- NORD — Gaucher Disease overview and clinical guidance
- ICGG Gaucher Registry — international natural-history and treatment-response dataset
- FDA National Drug Code Directory
- ASH / MGCC consensus guidance — Gaucher disease management
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer LSD ERT policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label | Event-driven | Tied to Takeda VPRIV PI version + FDA label revision date. |
| Brand class comparison (Cerezyme, Elelyso, Cerdelga, Zavesca) | Event-driven | Updated when any brand has an FDA label change, recall, supply disruption, or new indication. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS, Takeda
OnePath, payer documents, ICGG Gaucher Registry, NORD — all linked above). Editorial review in
progress. Until that review is complete, treat this as a draft reference and verify each cited source
for high-stakes claims.
Change log
- — SME audit pass. Boxed Warning corrected: current FDA label (revised Nov 26, 2024) carries a BOXED WARNING for hypersensitivity reactions including anaphylaxis — prior page text describing "no Boxed Warning" was inconsistent with the current label and has been corrected. DailyMed SetID added (ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf). HCPCS J3385 verified at 100 units per billing unit (Q2 2026 payment limit $388.157/unit).
- — Initial publication. ASP data: Q2 2026 ($388.157/billing unit, 100-unit basis). Manufacturer source: Takeda OnePath 2025 materials. FDA label: current revision (BLA 125249, originator Shire, transferred to Takeda following 2019 acquisition). Includes Gaucher class comparison (Cerezyme/VPRIV/Elelyso + oral SRT) and Cerezyme ↔ VPRIV switching guidance.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Diagnostic and dosing criteria reference the FDA label (BLA 125249), ICGG Gaucher Registry data, NORD Gaucher disease guidelines, and ASH/MGCC consensus guidance. We do not paraphrase from billing-software vendor blogs.